Cristiane Bergerot/X
Jun 1, 2025, 11:33
Cristiane Bergerot: Genomic Insights from IMmotion010
Cristiane Bergerot, Director of the Department of Psycho-Oncology at CETTRO Cancer Research Hospital, shared a post on X:
“Fascinating data from ASCO25!
Sumanta K. Pal presented genomic insights from IMmotion010 — KIM-1 remains the most robust predictor of atezo benefit, with NMF6 (stromal/proliferative) tumors also showing promising DFS. Important steps toward personalized adjuvant therapy in RCC.”
Bergerot commented on data presented by Sumanta K. Pal at ASCO25 from the IMmotion010 trial, highlighting KIM-1 and NMF6 as key biomarkers for guiding adjuvant atezolizumab therapy in renal cell carcinoma.
More posts featuring Cristiane Bergerot.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 2, 2025, 18:07
Jun 2, 2025, 18:00
Jun 2, 2025, 17:43
Jun 2, 2025, 17:18
Jun 2, 2025, 17:06
Jun 2, 2025, 15:40
Jun 2, 2025, 15:37
Jun 2, 2025, 15:20